8K filing hints at bullish developments for PSID Print E-mail
By M.E.Garza   
Wednesday, 26 January 2011 09:18
A new 8-K filing by PositiveID Corporation (NASDAQ: PSID) indicates that the company has partnered with AT&T Inc. (NYSE: T) to improve diabetes management through the companies’ innovative mobile technology.

It is believed that through this strategic relationship, AT&T will provide PositiveID with machine-to-machine (M2M) wireless data and mobile connectivity for real-time communication of a diabetes patient’s glucose readings, while PositiveID will provide its iglucose™ solution, which will also be incorporated with its Wireless Body™.

8K Filing from Positive ID

Interestingly, according to the new filing, it says that PSID will seek confidential treatment from the Securities and Exchange Commission for certain portions of the Agreement.

When contacted, Scott R. Silverman, Chairman and CEO of PositiveID Corporation, said, “As we continue to expand the development and breadth of our unique diabetes management products, partnering with one of the premier companies in the world, AT&T, is an important milestone for PositiveID.”

PositiveID’s iglucose (www.positiveidcorp.com/iglucose.html) is designed to take the work out of diabetes management by automatically creating logs and journals. It is conceivable that users would connect their data capable glucometer to iglucose and within seconds data would be transmitted via AT&T’s M2M network to the iglucose database. 

The Wireless Body communication system is built on PositiveID’s Patent No. 7,125,382 for an Embedded Bio-Sensor System, which builds upon the existing technology and intellectual property portfolio of PositiveID, the developer of the world's first and only health-related implantable RFID microchip cleared by the U.S. Food and Drug Administration. 

As you may recall from some of our previous articles about the company, they are doing some incredibly innovative work with implant chips while aiming to help patients monitor blood glucose levels without the use of needles. We see this as a very bullish development for PSID as it could set the table for other important announcements. We will keep you posted as we learn more.



"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter